GlassScriptPhysician profile
Steven M Sorenson
NPI 1437507068
$2,415.00
in general payments reported to CMS, 2019-2025
20 companies · $676 in 2025
The $676 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $128 · 2021: $189 · 2022: $206 · 2023: $379 · 2024: $601 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,458 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,457.88 |
| Education | $197.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $439.69 | 2023-2025 | Acthar |
| Alcon Vision LLC | $410.02 | 2019-2025 | Clareon, Tryptyr, Total30 |
| Glaukos Corporation | $274.10 | 2022-2025 | Istent Infinite, Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Dompe US, INC. | $196.19 | 2022-2025 | Oxervate |
| Amgen INC. | $150.00 | 2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $144.95 | 2024 | Syfovre |
| Bausch & Lomb Americas INC. | $141.87 | 2022-2025 | Xiidra, Infuse, Miebo |
| Allergan, INC. | $135.20 | 2019-2021 | |
| Ocular Therapeutix, INC. | $90.95 | 2024 | Dextenza |
| Kala Pharmaceuticals, INC. | $69.52 | 2019-2021 | |
| Horizon Therapeutics Plc | $60.18 | 2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $54.62 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $47.60 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $43.56 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $35.59 | 2020-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $31.54 | 2019 | |
| Oyster Point Pharma, INC. | $30.44 | 2022 | |
| Omeros Corporation | $22.23 | 2019 | |
| Harrow Eye, LLC | $21.50 | 2025 | Triesence |
| Shire North American Group INC | $15.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Sorenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.